Pathological and immunohistochemical examinations revealed the following histological subtypes among the 90 malignant breast tumors: Subtype Distribution: Luminal A:3 cases; Luminal B:53 cases; Triple-negative:16 cases; HER-2 overexpression:18 cases; Receptor Status: ER (Estrogen Receptor): ER-: 31 cases (34.4%); ER+: 59 cases (65.6%); PR (Progesterone Receptor): PR-: 32 cases (35.6%); PR+: 58 cases (64.4%); HER-2 (Human Epidermal Growth Factor Receptor 2): HER-2-: 63 cases (70%); HER-2+: 27 cases (30%); These distributions are illustrated in Figure 2. This evidence concerns the gene ERBB2 and breast neoplasm.